Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DROXIDOPA vs ABILIFY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Treatment of neurogenic orthostatic hypotension (n OH) in adult patients with primary autonomic failure (e.g., Parkinson's disease, multiple system atrophy, pure autonomic failure) or secondary autonomic failure (e.g., diabetes, amyloidosis)
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
2–3 hours; terminal half-life approximately 2.5 hours, requiring 3–4 times daily dosing to maintain plasma levels.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Metabolized by aromatic L-amino acid decarboxylase (AAAD) to norepinephrine, and also undergoes catechol-O-methyltransferase (COMT) metabolism.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Renal: ~75% as unchanged drug and metabolites (including 3-O-methyldroxidopa and other conjugates); biliary/fecal: minimal (<5%).
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
~75% (primarily to albumin).
>99% bound to albumin and alpha-1-acid glycoprotein.
1–1.5 L/kg; indicates extensive tissue distribution.
4.9 L/kg (high distribution into tissues).
Oral: ~40% (range 30–50%) due to first-pass metabolism.
Oral: 87% (tablet and solution); IM: 100%.
For GFR 15-29 m L/min: reduce dose to 100 mg twice daily. For GFR <15 m L/min or dialysis: 100 mg once daily or 100 mg every other day.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
No specific Child-Pugh based adjustments; contraindicated in severe hepatic impairment (Child-Pugh C). Use with caution in moderate impairment (Child-Pugh B) at reduced doses.
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Safety and efficacy not established in pediatric patients; no standard weight-based dosing available.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Start at lower end of dosing range (100 mg twice daily) due to increased risk of orthostatic hypotension and renal function decline; monitor blood pressure and adjust gradually.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
No FDA black box warning.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
May cause supine hypertension; monitor blood pressure and manage by reducing dose or discontinuing if severe.,Risk of exacerbation of cardiovascular disease (e.g., arrhythmias, heart failure).,May cause hyperthermia and confusion in patients with Parkinson's disease (resembles neuroleptic malignant syndrome).,Potential for increased risk of hallucinations or other psychiatric effects.,Use with caution in patients with pre-existing cerebrovascular or cardiovascular disease.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Hypersensitivity to droxidopa or any component of the formulation.,Use in patients with significant cardiovascular disease (e.g., unstable angina, recent myocardial infarction, or severe ventricular arrhythmias) is contraindicated.,Concomitant use with non-selective MAO inhibitors (e.g., phenelzine, tranylcypromine) due to risk of hypertensive crisis.
Known hypersensitivity to aripiprazole or any of its excipients.
Avoid alcohol as it may exacerbate hypotension. No specific food interactions known; take with or without food. High-tyramine foods (e.g., aged cheeses, cured meats) are not contraindicated but monitor blood pressure if consuming large amounts.
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
Pregnancy Category C. In animal studies, droxidopa caused decreased fetal weights and increased skeletal variations at doses 2.6 times the maximum recommended human dose. There are no adequate and well-controlled studies in pregnant women. Fetal risk cannot be ruled out; use only if potential benefit justifies potential risk to the fetus.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
No data available on presence in human milk, effects on breastfed infant, or milk production. Caution advised. M/P ratio unknown.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
No specific pharmacokinetic data in pregnancy; dose adjustment not recommended due to lack of evidence. Use lowest effective dose. Monitor for hypotension and supine hypertension.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
Droxidopa is a prodrug of norepinephrine used for symptomatic neurogenic orthostatic hypotension (NOH). Monitor supine hypertension closely; advise patients to avoid dose lying down. Onset of action is within 1 hour, peak effect at 3-4 hours, duration about 6-8 hours. Titrate based on symptoms and supine blood pressure. Do not administer within 5 hours of bedtime to reduce risk of nocturnal supine hypertension. Can be used with fludrocortisone or midodrine, but additive hypertension risk.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
Take droxidopa exactly as prescribed, usually three times daily: on waking, mid-day, and late afternoon—never within 5 hours of bedtime.,Do not lie down after taking a dose; remain upright (sitting or standing) to prevent severe high blood pressure while lying down.,Rise slowly from sitting or lying positions to reduce falls; symptoms of low blood pressure include dizziness, lightheadedness, and fainting.,Avoid alcohol, which can worsen low blood pressure and increase side effects like dizziness.,Report symptoms of high blood pressure when lying down: severe headache, blurred vision, chest pain, difficulty breathing.,Store at room temperature; keep away from moisture and heat.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
"Betahistine, a histamine analog, may reduce the therapeutic efficacy of droxidopa, a prodrug converted to norepinephrine for the treatment of symptomatic neurogenic orthostatic hypotension. The proposed physiological effect is that betahistine's H1- and H3-receptor agonistic and antagonistic activities could counteract the pressor response of norepinephrine, leading to suboptimal blood pressure elevation. Clinically, this may result in inadequate control of orthostatic hypotension symptoms, such as dizziness and syncope, when both agents are used concomitantly."
"Droxidopa, a synthetic amino acid converted to norepinephrine, directly elevates blood pressure, opposing the antihypertensive effects of mirtazapine. Mirtazapine, an atypical antidepressant with alpha-2 antagonism, may further enhance norepinephrine release, potentially synergizing with droxidopa's pressor effect. This interaction can lead to reduced efficacy of mirtazapine in managing hypertension and may increase risk of hypertensive crisis."
"Droxidopa, a prodrug of norepinephrine, is used to increase blood pressure in patients with neurogenic orthostatic hypotension. Tianeptine, an atypical antidepressant with opioid receptor activity, can cause bradycardia and hypotension. The combination may lead to an antagonistic effect where tianeptine's hypotensive properties reduce the pressor efficacy of droxidopa, potentially resulting in inadequate blood pressure control and recurrence of orthostatic hypotension symptoms."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DROXIDOPA vs ABILIFY, answered by our medical review team.
DROXIDOPA is a Vasopressor that works by Droxidopa is a synthetic precursor of norepinephrine that increases norepinephrine levels in the peripheral nervous system, thereby improving sympathetic tone and blood pressure regulation.. ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DROXIDOPA and ABILIFY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DROXIDOPA is: 100-200 mg orally three times daily, with a maximum of 600 mg three times daily if needed.. The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DROXIDOPA and ABILIFY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DROXIDOPA is classified as Category C. Pregnancy Category C. In animal studies, droxidopa caused decreased fetal weights and increased skeletal variations at doses 2.6 times the maximum recommended human dose. There are. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.